Eagle Pharmaceuticals Inc. (EGRX) announced that the U.S. Food and Drug Administration has approved Docetaxel Injection, Non-Alcohol Formula for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. Eagle entered into an exclusive licensing agreement with Teikoku Pharma USA Inc. in October 2015 to market, sell and distribute Docetaxel Injection in the U.S.
Eagle expects to begin shipping Docetaxel Injection in January 2016. Eagle estimates that annual sales of generic docetaxel are approximately $75 million.
Docetaxel Injection is the first alcohol-free formulation approved in the U.S.
Additional features of this product are: presents as one, pre-filled vial that does not require mixing; is available in three different dosages: 20mg/1ml, 80mg/4mL, and 160mg/8mL; and 24 hours of stability at final dilution strength.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.